

## References

- [1] M. Heung, L.S. Chawla, Predicting progression to chronic kidney disease after recovery from acute kidney injury, *Curr. Opin. Nephrol. Hypertens.* 21 (6) (2012) 628–634.
- [2] United States Renal Data System, *USRDS Annual Data Report: Epidemiology of Kidney Disease in the United States*, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2018.
- [3] M. Abbasi, G.M. Chertow, Y.N. Hall, End-stage renal disease, *BMJ Clin. Evid.* 2010 (2010).
- [4] A.S. Levey, L.A. Stevens, C.H. Schmid, Y.L. Zhang, A. F. Castro III, H.I. Feldman, J.W. Kusek, P. Eggers, F. Van Lente, T. Greene, J. Coresh, A new equation to estimate glomerular filtration rate, *Ann. Intern. Med.* 150 (9) (2009) 604–612.
- [5] V. Sakhuja, H.S. Kohli, End-stage renal disease in India and Pakistan: incidence, causes, and management, *Ethn. Dis.* 16 (2 Suppl 2) (2006) S2-20-3.
- [6] R.H. Rubin, J.S. Wolfson, A.B. Cosimi, N.E. Tolkoff-Rubin, Infection in the renal transplant recipient, *Am. J. Med.* 70 (2) (1981) 405–411.
- [7] L. Dupont, M.B. Reeves, Cytomegalovirus latency and reactivation: recent insights into an age old problem, *Rev. Med. Virol.* 26 (2) (2015) 75–89.
- [8] V.C. Emery, A.V. Cope, E.F. Bowen, D. Gor, P. D. Griffithsa, The dynamics of human cytomegalovirus replication in vivo, *J. Exp. Med.* 190 (2) (1999) 177–182.
- [9] S.A. Ross, Z. Novak, S. Pati, S.B. Boppana, Diagnosis of cytomegalovirus infections, *Infect. Disord. Drug Targets* 11 (5) (2011) 466–474.
- [10] J.D. Meyers, N. Flournoy, E.D. Thomas, Risk factors for cytomegalovirus infection after human marrow transplantation, *J. Infect. Dis.* 153 (3) (1986) 478–488.
- [11] S. Bataille, V. Moal, J. Gaudart, M. Indreies, R. Purgus, B. Dussol, C. Zandotti, Y. Berland, H. Vacher-Coponat, Cytomegalovirus risk factors in renal transplantation with modern immunosuppression, *Transpl. Infect. Dis.* 12 (6) (2010) 480–488.
- [12] C.N. Kotton, D. Kumar, A.M. Caliendo, A. Asberg, S. Chou, D.R. Snydman, U. Allen, A. Humar, International consensus guidelines on the management of cytomegalovirus in solid organ transplantation, *Transplantation* 89 (7) (2010) 779–795.
- [13] M. Sheikhan, A. Ghoreishi, Application of covariance matrix adaptation–evolution strategy to optimal control of hepatitis B infection, *Neural Comput. & Applic.* 23 (3) (2012) 881–894.
- [14] H. Laarabi, A. Abta, M. Rachik, J. Bouyaghroumni, Optimal antiviral treatment strategies of HBV infection model with logistic hepatocyte growth, *ISRN Biomath.* 2013 (17/20) (2013).
- [15] J.M. Ntaganda, M. Gahamanyi, Fuzzy logic approach for solving an optimal control problem of an uninfected hepatitis B virus dynamics, *Appl. Math.* 6 (9) (2015) 1524–1537.
- [16] O. Aghajanzadeh, M. Sharifi, S. Tashakori, H. Zohoo, Robust adaptive Lyapunov-based control of hepatitis B infection, *IET Syst. Biol.* 12 (2) (2018) 62–67.
- [17] S. Zhang, Y. Zhou, Dynamics and application of an epidemiological model for hepatitis C, *Math. Comput. Model.* 56 (1/2) (2012) 36–42.
- [18] K.O. Okosun, O.D. Makinde, Optimal control analysis of hepatitis C virus with acute and chronic stages in the presence of treatment and infected immigrants, *Int. J. Biomath.* 7 (2) (2014) 1–23.
- [19] S. Zhang, X. Xu, Dynamic analysis and optimal control for a model of hepatitis C with treatment, *Commun. Nonlinear Sci. Numer. Simul.* 46 (2017) 14–25.
- [20] J. Khodaei-Mehr, S. Tangestanizadeh, R. Vatankhah, M. Sharifi, Optimal neuro-fuzzy control of hepatitis C virus integrated by genetic algorithm, *IET Syst. Biol.* 12 (4) (2018) 154–161.
- [21] L.G. De Pillis, A. Radunskaya, A mathematical tumor model with immune resistance and drug therapy: an optimal control approach, *Comput. Math. Meth. Med.* 3 (2) (2001) 79–100.
- [22] N. Babaei, M.U. Salamci, Personalized drug administration for cancer treatment using model reference adaptive control, *J. Theor. Biol.* 371 (2015) 24–44.
- [23] H. Moradi, M. Sharifi, G. Vossoughi, Adaptive robust control of cancer chemotherapy in the presence of parametric uncertainties: a comparison between three hypotheses, *Comput. Biol. Med.* 56 (2015) 145–157.
- [24] M. Sharifi, H. Moradi, Nonlinear composite adaptive control of cancer chemotherapy with online identification of uncertain parameters, *Biomed. Signal Process. Control.* 49 (2019) 360–374.
- [25] P. Khalili, R. Vatankhah, S. Taghvaei, Optimal sliding mode control of drug delivery in cancerous tumour chemotherapy considering the obesity effects, *IET Syst. Biol.* 12 (4) (2018) 185–189.
- [26] M. Sharifi, H. Moradi, Nonlinear robust adaptive sliding mode control of influenza epidemic in the presence of uncertainty, *J. Process Control* 56 (2017) 48–57.
- [27] J. Arino, F. Brauer, P. van den Driessche, J. Watmough, J. Wu, A model for influenza with vaccination and antiviral treatment, *J. Theor. Biol.* 253 (1) (2008) 118–130.
- [28] J. Lee, J. Kim, H. Kwon, Optimal control of an influenza model with seasonal forcing and age-dependent transmission rates, *J. Theor. Biol.* 317 (2013) 310–320.
- [29] P. Ngina, R.W. Mbogo, L.S. Luboobi, Modelling optimal control of in-host HIV dynamics using different control strategies, *Comput. Math. Meth. Med.* 2018 (1) (2018) 1–18.
- [30] M.K. Bera, P. Kumar, R.K. Biswas, Robust control of HIV infection by antiretroviral therapy: a super-twisting sliding mode control approach, *IET Syst. Biol.* 13 (3) (2019) 120–128.
- [31] G.A. Ngwa, W.S. Shu, A mathematical model for endemic malaria with variable human and mosquito populations, *Math. Comput. Model.* 32 (7/8) (2000) 747–763.